DistantNews
Alzheimer's Drugs Hailed as 'Game-Changers' Show Limited Effect: Study
🇰🇷 South Korea /Health & Science

Alzheimer's Drugs Hailed as 'Game-Changers' Show Limited Effect: Study

From Dong-A Ilbo · (1d ago) Korean Critical tone

Translated from Korean, summarized and contextualized by DistantNews.

TLDR

  • A large-scale analysis suggests that Alzheimer's drugs targeting amyloid plaques have shown limited clinical benefit for patients.
  • While these drugs effectively remove amyloid plaques from the brain, they did not lead to significant improvements in cognitive function.
  • The findings challenge the long-held amyloid hypothesis and suggest a need to explore alternative treatment mechanisms for Alzheimer's.

Hopes were high for a new generation of Alzheimer's drugs designed to combat the disease by clearing amyloid plaques from the brain. Hailed as potential "game-changers," medications like lecanemab (Kisunla) and donanemab (Leqembi) received approvals in the US and EU, offering a glimmer of hope for patients and families grappling with this devastating condition.

Although there were statistically significant differences in early studies, this did not lead to clinically perceptible improvements for patients.

— Francesco NoninoLead researcher from Italy's IRCCS Institute, commenting on the limited clinical effectiveness of Alzheimer's drugs despite plaque reduction.

However, a comprehensive analysis published in the Cochrane Database of Systematic Reviews casts a shadow over these expectations. The study, which synthesized data from 17 clinical trials involving over 20,000 patients with mild cognitive impairment or early-stage Alzheimer's, found that while the drugs successfully reduced amyloid plaque buildup, this biological effect did not translate into meaningful improvements in cognitive function or disease progression for patients.

Clearing amyloid did not sufficiently support the hypothesis that it would benefit patients.

— Edo RichardCo-author from the Radboud University Medical Center in the Netherlands, explaining the study's findings on the amyloid hypothesis.

This outcome casts doubt on the long-standing "amyloid hypothesis," which posits that amyloid plaque accumulation is the primary driver of Alzheimer's disease. While researchers acknowledge the drugs' efficacy in clearing plaques, they emphasize that this alone may not be sufficient to halt or reverse cognitive decline. The study's findings suggest that the complex pathology of Alzheimer's may involve other factors, such as neuroinflammation and tau protein tangles, that are not adequately addressed by current anti-amyloid therapies.

The current generation of anti-amyloid therapies is clearly not meeting expectations.

— Bryce VisselAustralian neuroscientist commenting on the study's findings regarding the efficacy of anti-amyloid treatments.

The implications of this research are significant, prompting a re-evaluation of Alzheimer's treatment strategies. Experts are calling for a shift in research focus towards alternative mechanisms, such as targeting neuroinflammation and protecting neurons. While the current anti-amyloid drugs may offer some benefit, their limited clinical impact and high cost, coupled with potential side effects like brain swelling and microhemorrhages, necessitate a broader and more diversified approach to finding effective treatments for Alzheimer's disease.

The approval of lecanemab at the time had its effects somewhat exaggerated. This paper, through actual clinical data, has confirmed its limitations.

— Lee Chang-junDirector of the Research Center for Memory and Glial Cells at the Institute for Basic Science (IBS), providing a Korean perspective on the study's findings.
DistantNews Editorial

Originally published by Dong-A Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog